Dr. Pemmaraju on Clinical Trial Results of LCL161 in High-Risk Myelofibrosis

Naveen Pemmaraju, MD
Published: Tuesday, Dec 12, 2017



Naveen Pemmaraju, MD, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the clinical trial results for LCL161 in patients with intermediate or high-risk myelofibrosis.

Among the 38 patients treated at the time of analysis, 10 were responding for an overall response rate of 24% to 26%, explains Pemmaraju. The median age is 72-years-old.

Five patients have experienced long-term responses, says Pemmaraju, with response rates over 1 year. The 3 most common side effects were fatigue, nausea, and dizziness—similar to what was seen with solid tumors.
 


Naveen Pemmaraju, MD, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the clinical trial results for LCL161 in patients with intermediate or high-risk myelofibrosis.

Among the 38 patients treated at the time of analysis, 10 were responding for an overall response rate of 24% to 26%, explains Pemmaraju. The median age is 72-years-old.

Five patients have experienced long-term responses, says Pemmaraju, with response rates over 1 year. The 3 most common side effects were fatigue, nausea, and dizziness—similar to what was seen with solid tumors.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Archived Version of a Live Webcast: Virtual Current Trends™: European Perspectives on the Advancing Role of CAR T-Cell Therapy in Hematologic MalignanciesJun 29, 20192.0
Community Practice Connections™: Practical Application of Sequencing for EGFR-Mutant Lung Cancers: A Focus on Recent Evidence and Key Next Steps in TrialsJun 29, 20192.5
Publication Bottom Border
Border Publication
x